SCHEMBL770235

SCHEMBL770235

CC1CCN(C(=O)CCNC(=O)N2CCC3CCCCC3C2)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.49
ALDH1A1 P00352 5/20 0.45
LMNA P02545 2/20 0.39
HSD11B1 P28845 1/20 0.38
GNAI3 P08754 3/20 0.37
GNAO1 P09471 3/20 0.37
GNAI1 P63096 3/20 0.37
KMT2A Q03164 2/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CHRM1 P11229 2/20 0.37
MAPT P10636 2/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM3 P20309 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771047 0.92 NPC1 (0.54) NPC1ALDH1A1LMNAHSD11B1GNAI3
SCHEMBL770442 0.90 HSD11B1 (0.42) LMNAHSD11B1GNAI3GNAO1GNAI1
SCHEMBL770550 0.90 HSD11B1 (0.39) NPC1ALDH1A1LMNAHSD11B1GNAI3
SCHEMBL770232 0.89 ALDH1A1 (0.51) NPC1ALDH1A1LMNAKMT2AHPGD
SCHEMBL770938 0.84 NPC1 (0.59) NPC1ALDH1A1LMNAHSD11B1GNAI3
SCHEMBL771470 0.83 NPC1 (0.41) NPC1ALDH1A1LMNAHSD11B1GNAI3
SCHEMBL770918 0.82 ITGB3 (0.45) LMNAHSD11B1CHRM1
SCHEMBL769711 0.82 NPC1 (0.70) NPC1ALDH1A1LMNAHSD11B1GNAI3
SCHEMBL769996 0.82 NPC1 (0.65) NPC1ALDH1A1LMNAHSD11B1GNAI3
SCHEMBL769690 0.82 KMT2A (0.55) NPC1ALDH1A1LMNAKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 97/4885ALDH1A1 144/4885LMNA 3155/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 104/4885ALDH1A1 142/4885LMNA 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.